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Background/Aims: Spinal metastases often severely limit the 
quality of life by causing severe pain and neurological deficits. 
The purpose of this study was to evaluate the palliative effect 
of radiotherapy (RT) for spinal metastases from hepatocellular 
carcinoma (HCC) and to identify factors predictive of survival 
in HCC patients with spinal metastases who received RT. Meth-
ods: A retrospective analysis was performed on 192 patients 
with spinal metastases from HCC who received RT. Results: Of 
192 patients with spinal metastases from HCC, an overall pain 
response to palliative RT occurred in 187 patients (97.4%), with 
a complete pain response (CR) in 41 patients (21.4%) and a par-
tial response in 151 patients (78.6%). A higher biologically ef-
fective dose (BED) and more advanced RT techniques were iden-
tified as predictive factors for a CR. The 1- and 2-year overall 
survival (OS) rates were 18.1% and 6.3%, respectively, and the 
median survival time was 4.5 months. A long OS was associated 
with good performance status, controlled primary HCC, absence 
of extrahepatic metastases, and a higher BED. Conclusions: 
RT provided effective palliation for patients with painful spinal 
metastases from HCC. Our results provide information regarding 
pain control, survival outcomes, and predictive factors for the 
prognosis of HCC patients with spinal metastases treated with 
RT. (Gut Liver 2015;9:94-102)
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INTRODUCTION
The development of various diagnostic tools and treatment 
modalities has improved the survival of hepatocellular carcinoma 
(HCC) patients. Consequently, bone metastases from HCC are di-
agnosed more frequently.1 Approximately 5% to 25% of HCC pa-
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tients have bone metastases.2-5 The spine is the most frequent bone 
metastatic site in HCC, and spinal metastases have been reported 
to occur in approximately 50% to 75% of patients with bone me-
tastases from HCC.2,5-7 Spinal metastases often severely limit the 
quality of life, causing severe pain and neurological deficits.
Radiotherapy (RT) can provide significant palliation of pain-
ful bone metastases in approximately 60% to 90% of patients, 
with up to 33% of patients achieving complete pain response (CR) 
at the irradiated site.8,9 At our institute, RT has been actively 
adopted in the management of bone metastases from HCC, par-
ticularly for those causing pain. We and others have previously 
reported that RT provides effective palliation for patients with 
painful bone metastases from HCC during the substantial me-
dian survival time.2,5,7,10
Previous studies have suggested that prognostic factors, in-
cluding unfavorable primary tumor type, extrahepatic metas-
tases, multiple bone metastases, and performance status, could 
predict overall survival (OS) in patients with spinal metastases 
from various solid tumors who receive RT.11,12 However, little 
is known about the predictive factors associated with pain 
response and survival in RT-treated patients with spinal me-
tastases from HCC. Prediction of survival and pain response 
are important in determining proper management, including 
the optimal RT schedule for patients with symptomatic spinal 
metastases. The purpose of this study was to evaluate the pallia-
tive effect of RT for spinal metastases from HCC and to identify 
predictive factors of survival in RT-treated patients with spinal 
metastases from HCC.
MATERIALS AND METHODS
1. Patients
Between April 1992 and February 2012, 192 HCC patients 
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underwent palliative RT for spinal metastases at 383 sites at our 
hospital. HCC diagnoses were confirmed radiologically (hyperat-
tenuation in the arterial phase and washout in the late phase) 
using either contrast-enhanced computed tomography (CT) or 
magnetic resonance imaging (MRI).13 Ultrasound-guided tumor 
biopsies were performed in patients with inconclusive diagnostic 
imaging results. Pretreatment evaluation included medical his-
tory taking and physical examination, complete blood cell count, 
serum chemistries, liver function tests, serum α-fetoprotein (AFP) 
measurement, and diagnostic imaging studies. Liver function 
was estimated using the Child-Pugh classification, scored ac-
cording to bilirubin and albumin serum levels, prothrombin time 
prolongation, presence or absence of ascites, and encephalopa-
thy. Patients without new lesions or primary tumor progression 
on the follow-up enhanced CT and/or MRI after primary treat-
ments against HCC were regarded as having controlled primary 
tumors. A newly detected hepatic nodule will be defined as new 
lesions when its longest diameter is at least 1 cm and the nodule 
shows the typical vascular pattern of HCC on dynamic imaging, 
that is, hypervascularization in the arterial phase with washout 
in the portal venous or late venous phase.14 Otherwise, patients 
were regarded as having uncontrolled primary tumors.
2. Diagnosis and evaluation of spinal metastases
Bone metastases were diagnosed using imaging studies plus 
the serum AFP level or biopsy and histological study. Character-
istics of spinal metastases were evaluated using imaging studies 
including plain radiography, whole body bone scintigraphy, CT, 
MRI, and positron emission tomography. Tumor characteristics 
included multiplicity of spinal metastases, mass-type metastases, 
spinal cord compression, and pathological fracture secondary to 
metastatic lesions. Mass-type metastasis was defined as an ex-
pansile soft-tissue lesion with a clear boundary outside the spine. 
Spinal cord compression was defined as radiological tumor in-
volvement of the spinal canal with severely impaired neurologi-
cal function (American Spinal Injury Association impairment 
scale of A, B, or C).15 Only patients with pathologic fracture due 
to secondary malignancy were included in the study.
3. Pain assessment
Subjective pain response to treatment was assessed using 
the Brief Pain Inventory (BPI).16 The BPI assesses pain severity 
as “worst,” “least,” “average,” and “now” (current pain). In our 
study, the item “worst” was used to indicate pain severity. The 
numeric rating scale ranged from 0 to 10 (0, no pain and 10, 
pain as bad as can be imagined). Patients were interviewed by a 
physician before the start of RT, 2 weeks after RT, and every 3 
months thereafter for 1 year. Pain response to treatment was de-
fined according to the International Bone Metastases Consensus 
Working Party palliative RT endpoints.17 CR was defined as a 
zero pain score at the treated site with no concomitant increase 
in daily oral morphine equivalent analgesic intake. Partial re-
sponse (PR) was defined as either pain reduction of 2 or more 
points below baseline at the treated site on a 0-10 scale without 
analgesic increase or analgesic reduction of 25% or more from 
baseline without an increase in pain. Pain progression (PP) was 
defined as pain increase of 2 or more points above baseline at 
the treated site with stable analgesic use or a stable pain score 
or 1 point above baseline with an increase of 25% or more in 
daily oral morphine equivalent. Patients not classified as having 
CR, PR, or PP were considered as having stable pain (SP). 
4. Treatment
For spinal metastases, the radiation dose was prescribed to the 
mid-vertebral body. In the case of conventional 2-dimensional 
RT, radiation fields usually involved 1 normal vertebra above 
and below the metastatic lesion. The portion adjacent to the 
gross tumor volume (GTV) was included in the clinical target 
volume (CTV) in a radiation port using a 3-dimensional con-
formal RT (3D-CRT) or intensity-modulated radiation therapy 
(IMRT) planning system. For example, if the GTV involved the 
pedicle and lateral part of the vertebral body, the CTV encom-
passed the vertebral body, pedicle, transverse process, and lam-
ina. The spinous process, contralateral pedicle, and lamina were 
excluded from the CTV. For postoperative treatment, the surgi-
cal bed was included from the CTV. Planning target volume 
(PTV) modification (0 to 1 cm) was allowed if the CTV extended 
to critical organs other than the normal spine. Total doses were 
recalculated and normalized to obtain biologically effective 
doses (BEDs) as the α/β ratio=10 Gy. The actual total dose was 
converted to BED as follows: BED=nd [1+d/(α/β)], where n is 
the number of fractions, and d, the dose per fraction. Calculated 
BED values ranged from 14.4 to 78 Gy10 with a median dose 
of 44.2 Gy10. Patients were immobilized in thermoplastic head-
shoulder masks for the cervical spine. For the thoracic and lum-
bar spine, a customized total body vacuum bag was used.
In addition to RT, surgical decompression with or without in-
strumentation and systemic chemotherapy, including cisplatin, 
5-fluorouracil, and sorafenib, and so on, were performed to re-
lieve pain and prevent impending neurological deficit from spi-
nal metastases. None of the patients received bisphosphonates 
to reduce the risk of skeletal-related events and the loss of bone 
mass. 
5. Toxicity assessment
Radiation Therapy Oncology Group criteria were used to as-
sess treatment-related toxicity. Acute reaction during RT was 
assessed from patient records, and the occurrence of radiation-
induced myelopathy was identified as late toxicity. 
6. Statistical analysis
Categorical variables are summarized using frequencies and 
percentages. To determine the association between pain re-
sponse and covariates, univariate analysis was performed using 
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the nonparametric Pearson chi-square or Fisher exact test. A 
receiver operating characteristic curve was used to select single 
cutoff value for various continuous variables. Likelihood ratio 
were used to select two contiguous cutoff values for the interval 
of a continuous variable. Multivariate analyses were performed 
using a stepwise logistic regression model. OS after diagnosis of 
spinal metastases was defined as the interval from the date of 
first observation of spinal metastases on CT or MRI to the date 
of death or last follow-up appointment. Survival was calculated 
using the Kaplan-Meier method. The log-rank test was used 
to examine the differences between survival curves for each 
potential predictive factor. Multivariate survival analyses were 
performed using a Cox proportional hazard model. All statistical 
analyses were performed using SPSS version 18.0 (SPSS Inc., 
Chicago, IL, USA). A p-value of less than 0.05 was considered 
statistically significant.
RESULTS
1. Clinical features of spinal metastases
Patient, tumor, and treatment characteristics are summarized 
Table 1. Patient, Tumor, and Treatment Characteristics (n=192)
Characteristic Value
Age, yr 56 (20–82)
Gender
    Male 157 (81.8) 
    Female 35 (18.2) 
ECOG performance status
    0 16 (8.3) 
    1 33 (17.2) 
    2 55 (28.6) 
    3 66 (34.4) 
    4 22 (11.5) 
AFP, ng/mL 245.2 (1–120,000)
Child-Pugh classification
    A 130 (67.7) 
    B 42 (21.9) 
    C 20 (10.4) 
Primary HCC 
    Controlled 127 (66.1) 
    Uncontrolled 65 (33.9) 
Interval from diagnosis of primary tumor to 
spinal metastases, mo
8.6 (0–127)
Baseline BPI score (pain severity) 5.0 (2–10)
Extrahepatic metastases other than bone*
    Yes 50 (26.0) 
    No 142 (74.0) 
Sites of spinal metastases
    Cervical 26 (13.5) 
    Thoracic 46 (24.0) 
    Lumbar 48 (25.0) 
    Sacrum 8 (4.2) 
    Combined (2 sites or more) 64 (33.3) 
Multiplicity of spinal metastases
    Yes 105 (54.7) 
    No 87 (45.3) 
Mass-type metastases
    Yes 46 (24.0) 
    No 146 (76.0) 
Spinal cord compression (ASIA scale A-C)
    Yes (A–C) 25 (13.0) 
    No (D–E) 167 (87.0) 
Pathologic fracture
    Yes 47 (24.4) 
    No 145 (75.6) 
BED, Gy10
    ≤38 38 (19.8)
    39–53 132 (68.7)
    >53 22 (11.5)
Table 1. Continued
Characteristic Value
Treatment modalities
    RT alone 140 (72.9) 
    RT+systemic chemotherapy† 38 (19.8) 
    RT+surgical decompression 12 (6.3) 
    RT+systemic chemotherapy†+surgical 
decompression
2 (1.0) 
RT technique
    Conventional 107 (55.7) 
    3D-CRT 67 (34.9) 
    IMRT 18 (9.4) 
Interval from diagnosis of spinal metasta-
ses to start of RT, day
7.0 (0–187)
Data are presented as median (range) or number (%).
ECOG, Eastern Cooperative Oncology Group; AFP, α-fetoprotein; 
HCC, hepatocellular carcinoma; BPI, Brief Pain Inventory; ASIA, 
American Spinal Injury Association (A, no motor or sensory neuro-
logical function is preserved at or below sacral segments S4-5; B, in-
complete sensory function but motor function is not preserved below 
the neurological level, extending through sacral segments S4-5; C, 
incomplete motor function but normal sensory function is preserved 
below the neurological level, and the majority of key muscles below 
the neurological level have a muscle power of grade <3; D, motor 
function is preserved below the neurological level, and the majority 
of key muscles below the neurological level have a muscle power of 
grade ≥3; E, normal motor and sensory function); BED, biologically 
effective dose; RT, radiotherapy; 3D-CRT, 3-dimensional conformal 
radiation therapy; IMRT, intensity-modulated radiation therapy.
*Including lung, lymph nodes, brain, and adrenal gland; †Including 
five patients who received sorafenib.
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in Table 1. Of the 192 patients, 181 (94.3%) were followed up 
until death. During this time, 11 patients (5.7%) were lost to fol-
low-up. The median follow-up duration was 4.2 months (range, 
0.5 to 124.8 months). Forty-eight patients (25%) presented with 
synchronous metastases and 144 (75%) presented with meta-
chronous metastases. The most commonly involved site on the 
spine was the lumbar vertebrae (48/192; 25%), followed by the 
thoracic vertebrae (46/192; 23.9%). Solitary spine metastasis 
was observed in 87 patients (45.7%), and ≥2 spine metastases 
were present in 105 patients (54.7%). 
2. Pain response
Of the 192 patients with spinal metastases from HCC who 
received RT, 187 (97.4%), 41 (21.4%), 146 (78.6%), 3 (1.6%), 
and 2 (1.0%) showed overall pain response (CR+PR), CR, PR, 
SP, and PP, respectively (Table 2). Tumor and treatment char-
Table 2. Univariate Analysis to Identify Predictive Factors for the Pain Response
Variable
No. of 
patients 
Response
(CR+PR)*
Nonresponse
(SP+PP)*
p-value† CR Non-CR p-value†
Multiplicity of spinal metastases 0.388 0.739
    Yes 105 (54.7) 104 (54.2) 1 (0.5) 17 (8.9) 88 (45.8)
    No 87 (45.3) 83 (43.2) 4 (2.1) 24 (12.5) 63 (32.8)
Mass-type metastases 0.080 0.734
    Yes 46 (24.0) 42 (21.9) 4 (2.1) 9 (4.7) 37 (19.3)
    No 146 (76.0) 145 (75.5) 1 (0.5) 32 (16.7) 114 (59.3)
Spinal cord compression (ASIA scale A–C) 0.304 0.221
    Yes (A–C) 25 (13.0) 21 (10.9) 4 (2.1) 3 (1.6) 22 (11.4)
    No (D–E) 167 (87.0) 166 (86.5) 1 (0.5) 38 (19.8) 129 (67.2)
Pathologic fracture 0.598 0.013
    Yes 47 (24.4) 45 (23.4) 2 (1.0) 4 (2.1) 43 (22.3)
    No 145 (75.6) 142 (74.0) 3 (1.6) 37 (19.3) 108 (56.3)
BED, Gy10 0.711 <0.001
    ≤38 38 (19.8) 37 (19.3) 1 (0.5) 4 (2.1) 34 (17.7)
    39–53 132 (68.7) 128 (66.6) 4 (2.1) 24 (12.5) 108 (56.2)
    >53 22 (11.5) 22 (11.5) 0 13 (6.8) 9 (4.7)
Treatment modalities 0.335 0.093
    RT alone 140 (72.9) 136 (71.9) 4 (1.0) 25 (13.0) 115 (59.9)
    RT+CTx 38 (19.8) 38 (19.8) 0 13 (6.8) 25 (13.0)
    RT+S±CTx 14 (7.3) 13 (6.8) 1 (0.5) 3 (1.6) 11 (5.7)
RT technique 0.067 0.002
    Conventional 107 (55.7) 102 (53.1) 5 (2.6) 14 (7.3) 93 (48.4)
    3D-CRT or IMRT 85 (44.3) 85 (44.3) 0 27 (14.1) 58 (30.2)
Total 192 (100.0) 187 (97.4) 5 (2.6)  41 (21.4) 151 (78.6)  
Data are presented as number (%).
CR, complete pain response; PR, partial response; SP, stable pain; PP, pain progression; ASIA, American Spinal Injury Association; BED, biologi-
cally effective dose; RT, radiotherapy; CTx, chemotherapy; S, surgery; 3D-CRT, 3-dimensional conformal radiation therapy; IMRT, intensity-
modulated radiation therapy.
*CR, 41 patients (21.4%); PR, 146 patients (76.0%); SP, 3 patients (1.6%); PP, 2 patients (1.0%); †Determined using Pearson chi-square or Fisher 
exact test.
Table 3. Multivariate Analysis to Identify Predictive Factors for a 
Complete Pain Response
Variable
CR
OR 95% CI p-value*
Pathologic fracture 0.415 1.516–0.114 0.184
BED, Gy10
† 0.003
    39–53 0.555 1.726–0.179 0.309
    >53 0.296 0.659–0.133 <0.001
RT technique 0.358 0.778–0.165 0.009
CR, complete pain response; OR, odds ratio; CI, confidence interval; 
BED, biologically effective dose; RT, radiotherapy.
*Determined using stepwise logistic regression analysis; †Reference 
level of a BED was ≤38 Gy10.
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Table 4. Univariate and Multivariate Analyses to Identify Predictive Factors for Overall Survival
Variable
Univariate analysis Multivariate analysis
No. of patients Median survival±SE, mo p-value* Coefficient HR 95% CI p-value†
Age, yr 0.492
    ≤55 86 4.8±0.5
    >55 106 3.9±0.5
Gender 0.430
    Male 157 4.5±0.3
    Female 35 5.3±1.7
ECOG performance status <0.001 0.639 1.895 1.302–2.757 0.001
    0–2 104 5.7±0.3
    3–4 88 2.7±0.3
AFP, ng/mL 0.143
    ≤200 98 4.7±0.5
    >200 94 2.8±0.6
Child-Pugh classification 0.025 0.259 1.165 0.693–1.755 0.164
    A, B 172 4.5±0.4
    C 20 2.0±1.2
Primary HCC <0.001 1.279 3.595 2.453–5.268 <0.001
    Controlled 127 6.2±0.5
    Uncontrolled 65 1.9±0.3
Interval from diagnosis of primary tumor  
to spinal metastases, mo
0.966
    ≤9 100 4.2±0.5
    >9 92 4.0±0.7
Baseline BPI score (pain severity) 0.857
    ≤6 114 4.8±0.6
    >6 78 4.2±0.5
Extrahepatic metastases other than bone 0.012 -0.560 0.571 0.391–0.835 0.004
    Yes 50 2.8±0.6
    No 142 5.0±0.5
Sites of spinal metastases 0.169
    Cervical 26 2.5±1.3
    Thoracic 46 4.8±0.4
    Lumbar 48 5.7±1.4
    Sacrum 8 4.5±2.8
    Combined (2 sites or more) 64 3.7±0.6
Multiplicity of spinal metastases 0.112
    Yes 105 5.0±0.5
    No 87 3.9±0.7
Mass-type metastases 0.577
    Yes 46 4.7±1.7
    No 146 4.5±0.4
Spinal cord compression (ASIA scale A–C) 0.839
    Yes (A–C) 25 4.0±2.0
    No (D–E) 167 4.5±0.4
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acteristics were not associated with overall pain response. In 
univariate analysis, presence of pathologic fracture (p=0.013), 
BED (p<0.001), and RT technique (p=0.002) were identified as 
predictive factors for CR. Multivariate analysis revealed that 
predictive factors for CR were a higher BED (p=0.003) and a 
more advanced RT technique (3D-CRT or IMRT) (p=0.009) (Table 
3).
3. Survival analysis
The OS rates at 1 and 2 years after spinal metastasis diagnosis 
were 18.1% and 6.3%, respectively, and the median survival 
time was 4.5 months (95% confidence interval, 3.7 to 5.3). Uni-
variate analysis showed that good Eastern Cooperative Oncolo-
gy Group (ECOG) performance status (p<0.001) and Child-Pugh 
classification (p=0.025), a controlled primary HCC (p<0.001), 
absence of extrahepatic metastases (p=0.012) and pathologic 
fracture (p=0.003), a higher BED (p<0.001), and occurrence of 
CR (p=0.001) were significantly associated with better survival. 
Multivariate analysis revealed that predictive factors for better 
survival were good ECOG performance status (p=0.001), pres-
ence of controlled primary HCC (p<0.001), absence of extrahe-
patic metastases (p=0.004), and a higher BED (p<0.001) (Table 4).
Patients were classified into four groups according to the 
number of unfavorable risk factors for OS: poor performance 
status (ECOG 3-4), presence of uncontrolled primary HCC, and 
presence of extrahepatic metastases. One hundred three patients 
were classified as group A (0 risk factors), 71 as group B (1 risk 
factor), 16 as group C (2 risk factors), and 2 as group D (3 risk 
Table 4. Continued
Variable
Univariate analysis Multivariate analysis
No. of patients Median survival±SE, mo p-value* Coefficient HR 95% CI p-value†
Pathologic fracture 0.003 -0.342 0.710 0.476–1.059 0.093
    Yes 47 2.7±0.5
    No 145 5.0±0.3
BED, Gy10 <0.001 -0.624 0.536 0.383–0.751 <0.001
    ≤38 38 2.4±0.6
    39–53 132 9.7±1.6
    >53 22 15.2±4.2
Treatment modalities 0.926
    RT alone 140 3.9±0.6
    RT+CTx 38 4.0±1.3
    RT+S±CTx 14 5.3±0.6
RT technique 0.110
    Conventional (2D) 107 3.9±0.6
    3D-CRT or IMRT 85 4.5±0.7
Pain response 0.001 0.308 1.361 0.938–1.973 0.104
    CR 41 7.2±1.8
    Non-CR 151 3.0±0.4      
SE, standard error; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; AFP, α-fetoprotein; HCC, hepatocellular 
carcinoma; BPI, Brief Pain Inventory; ASIA, American Spinal Injury Association; BED, biologically effective dose; RT, radiotherapy; CTx, chemo-
therapy; S, surgery; 2D, 2-dimensional; 3D-CRT, 3-dimensional conformal radiation therapy; IMRT, intensity-modulated radiation therapy; CR, 
complete pain response.
*Determined using the log-rank test; †Determined using the Cox proportional hazard model.
Fig. 1. Stratified cumulative survival curves according to risk factor 
group. Risk factors were poor performance status (Eastern Coopera-
tive Oncology Group 3-4), uncontrolled primary hepatocellular car-
cinoma, and the presence of extrahepatic metastases. Group A, 0 risk 
factors; group B, 1 risk factor; group C, 2 risk factors; group D, 3 risk 
factors. p-values were determined using the log-rank test.
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factors). The median survival times were 5.7, 4.0, 1.5, and 1.0 
months in groups A, B, C, and D, respectively (Fig. 1). Subgroup 
analyses revealed that median survival time was significantly 
different between groups A and B (p=0.040), groups A and C 
(p<0.001), groups A and D (p<0.001), groups B and C (p=0.006), 
and groups B and D (p=0.013), but not between groups C and D 
(p=0.312). Our findings suggested that a higher BED might be 
associated with long OS in HCC patients with spinal metastases 
(Fig. 2).
4. Radiation-induced toxicity
Two patients experienced grade 3 neutropenia and anemia. 
No other severe (grade 3-4) acute toxicity was observed. Radia-
tion-induced myelopathy was not observed during the follow-
up period for the entire study population.
DISCUSSION
The spine is the most common site of bone metastases from 
HCC. Spinal metastases frequently result in neurological deficit 
and severe pain, which affect functional capacity and quality of 
life.2,5-7 The treatment goals for spinal metastases are pain relief 
and bone stabilization. RT is a well-established effective treat-
ment for alleviation of pain secondary to bone metastases from 
HCC.2,5,7,10
Metastatic bone pain is a multifactorial process. A relation-
ship between tumor burden and overall pain response has not 
been established.10 The pain caused by bone metastases is un-
likely to originate from the tumor burden but can originate not 
only from bone itself but also from nerve root compression or 
muscle spasm in the lesion area.18,19 Pain relief generally occurs 
after palliative RT with relatively low doses prior to the onset of 
radiological response. This early pain response may be related to 
a reduction in inflammatory cells, which release chemical pain 
mediators in the bone metastatic microenvironment.19,20 These 
reports support our result that patients who received RT showed 
overall pain response rate of 97.4%.
In the present study, we determined whether pain relief could 
be predicted using tumor characteristics and treatment modali-
ties of spinal metastases from HCC. Tumor characteristics and 
treatment modalities were not significantly associated with 
overall pain response. Hence, all patients with painful spinal 
metastases from HCC, regardless of spinal assessment criteria 
in imaging studies, including presence of mass-type metas-
tasis, pathologic fracture, and spinal cord compression, may 
obtain similar benefits from RT. However, higher CR rates were 
obtained with a higher BED or more advanced RT technique. 
Dose-response relationship studies have been mostly limited to 
comparing single-fraction versus multiple-fraction RT and have 
shown a higher rate of pain relapse with the single-fraction 
scheme.9,21,22 To date, the correlation between BED levels and 
CR has not been investigated. It is not clear why higher BEDs 
were associated with CR in our study. Considering that tumor 
cell-secreted inflammatory cytokines are a major source of bone 
pain,19,20 higher BED radiation may be more effective in sup-
pressing cytokine production by tumor cells. Further studies are 
investigating the underlying mechanisms of RT-mediated pain 
relief for bone metastases. We found that CR was significantly 
associated with the RT technique. More advanced RT techniques 
such as 3D-CRT and IMRT enabled radiation of a higher BED to 
be targeted more accurately to metastatic lesions while lowering 
the dose to normal organs, including the spinal cord. 
In our study, the 1-year and 2-year OS rates were 18.1% 
and 6.3%, respectively, and the median survival time was 4.5 
months. ECOG performance status is a significant independent 
predictive factor for survival in many cancer types, including 
HCC. We found that good ECOG performance status was sig-
nificantly associated with better survival in HCC patients with 
spinal metastases. The major cause of death in HCC patients 
with extrahepatic metastases, including bone metastases, is pro-
gression of the primary HCC lesion.7,23,24 This may be because 
liver function is strongly correlated with performance status. In 
our study, the presence of extrahepatic metastases other than in 
bone was found to be a significant negative prognostic factor 
for OS in HCC patients. However, most extrahepatic metastatic 
lesions were found not to be the direct cause of death in most 
affected HCC patients, with the exception of respiratory failure 
due to bilateral lung metastasis and cerebral hemorrhage due to 
brain metastasis.23 Hence, the presence of extrahepatic metas-
tasis may be an indicator of primary HCC aggressiveness as a 
whole rather than an independent predictive factor.
In our study, we identified poor ECOG performance status (3 
or 4), uncontrolled primary HCC, and the presence of extrahe-
patic metastases as risk factors for shorter overall survival in 
HCC patients with spinal metastasis who underwent RT. Patients 
with two or more risk factors had a significantly shorter median 
survival than those with no risk factors (≤1.5 months vs ≥5.7 
months). Patients with no risk factors should be considered for 
Fig. 2. Stratified cumulative survival curves according to biologically 
effective dose. p-values were determined using the log-rank test.
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intensive care, including treatments for intrahepatic or extra-
hepatic lesions. Dose-escalated RT (a minimum BED ≥39 Gy10) 
was also associated with prolonged OS in our study. The dose-
escalated RT regimen appears to be safe and feasible for patients 
without any risk factors. Because higher BEDs were associated 
with higher CR rates in our study, poor performance status due 
to severe bone pain might be improved after dose-escalated RT, 
and the improved performance status might be associated with 
prolonged OS. But dose escalation might be more frequently ad-
ministered to patients with good performance status for whom 
long-term survival was predicted. Therefore, this result should 
be carefully interpreted because all retrospective studies could 
always be exposed by a possibility of potential selection bias, 
and by confounding factors that are not easy to adjust for. The 
significance of dose escalation in palliative RT for spinal me-
tastases from HCC should be further investigated in large-scale 
prospective studies.
In our study, among 192 HCC patients, 23 had additional 
treatments after local failure following initial RT. Thirteen pa-
tients received re-irradiation, two underwent surgical decom-
pression, six received systemic chemotherapy, and two received 
combined treatment. In re-irradiation cases, the response to re-
irradiation was not included in the primary outcome of the first 
RT. Late toxicity was not observed in any of the patients who 
received additional treatments. Furthermore, these patients had 
a longer median survival than patients who did not receive ad-
ditional treatments (7.7 months vs 3.9 months). All patients who 
received additional treatment had good ECOG performance sta-
tus (0, 1, or 2) and ≤1 risk factor, which suggested the necessity 
of additional treatments in HCC patients with initial RT failure. 
In conclusion, RT provides effective palliation for patients 
with painful spinal metastases from HCC. In particular, RT with 
a higher BED may improve pain control and OS in these pa-
tients. The results of this study provide information regarding 
pain control, survival outcomes, and predictive factors for the 
prognosis of HCC patients with spinal metastases treated with 
RT. 
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